Video

WCLC Updates in Neoadjuvant Therapy for NSCLC

Author(s):

Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Sarah Goldberg, MD, MPH, Yale School of Medicine

Experts in thoracic oncology discuss the role of single-agent immunotherapy as neoadjuvant therapy and comment on the viability of MPR [major pathologic response] as a surrogate endpoint for non–small cell lung cancer (NSCLC).

Data from the following clinical trial are discussed: 

  •  PS01.05 - Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
Related Videos
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Related Content
OncLive’s December Roundup of Key FDA Approvals in Oncology
December 30th 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Non–Small Cell Lung Cancer | Image Credit: © Katsyarina – stock.adobe.com
December 30th 2024

T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

FDA
December 23rd 2024

FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC

Lung cancer, Image credit: Axel Kock – stock.adobe.com
December 23rd 2024

Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC